Neurocrine Tardive Dyskinesia Drug Enters Phase II of Clinical Trials

On Sept. 19, 2011, Neurocrine Biosciences Inc. announced that phase II clinical trial of a new drug to treat tardive dyskinesia has begun. The drug, labeled as NBI-98854, works by controlling the release of dopamine, a neurotransmitter that affects movement.

According to Christopher F. O’Brien, chief medical officer for Carmel Valley-based Neurocrine, there are 32 participants in the placebo-controlled study. The North County Times reports that results from the trial will help the company determine the dose and treatment for larger studies that are planned to begin in 2012.

The drug might also help with symptoms of other disease such as Huntington’s, schizophrenia, Tourette’s syndrome and tardive dystonia, according to Neurocrine.

(Source: North County Times)